Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ReGenTree LLC

Division of GtreeBNT Co. Ltd.
www.regentreellc.com

Latest From ReGenTree LLC

Deal Watch, Focus On Acquisitions: Emergent Acquires PaxVax, Pair Of Commercialized Vaccines

Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.

Deals M & A

FDA Tells RegeneRx It Needs 3rd Phase III Trial On RGN-259 For Dry Eye Syndrome

The FDA is requiring an additional RGN-259 Phase III trial to further show efficacy in both signs and symptoms of dry eye in a larger patient population.

Analysis Approvals

Pipeline Watch: Patisiran, Etrolizumab, ALKS8700 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Mixed Results From ReGenTree's DES Therapy In Second Phase III

ReGenTree has reported mixed results in its second pivotal Phase III trial of RGN-259 indicating that the therapy is most effective in patients with severe dry eye. The results raise some doubts about the treatment’s potential approval for the general dry eye population.

Research & Development Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • G-treeBNT-RegeneRx joint venture
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • GtreeBNT Co. Ltd.
  • Senior Management
  • Contact Info
  • ReGenTree LLC
    Phone: (609) 734-4328
    116 Village Blvd.
    Ste. 200
    Princeton, 08540
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register